Statements

Find out what Breast Cancer Care is saying about the latest drug treatments, research papers and health policy issues.

If you’re working on a story and need an expert quote, call us on 0345 092 0807 (out of hours 07702 901 334).

Responding to the findings published today (Thursday 18 January) in the Journal of the National Cancer Institute, suggesting that screening the entire...

Responding to updated NICE draft guidance on breast cancer profiling tests Dr Emma Pennery, Clinical Director of Breast Cancer Care, says:...

Responding to the decision by NICE (on Thursday 14 December 2017) to not recommend fulvestrant (Faslodex) for use by the NHS in England*, Samia al Qadhi...

Responding to findings presented at the 2017 San Antonio Breast Cancer Symposium on weight loss and breast cancer risk, Addie Mitchell, Clinical Nurse...

Responding to the news that the Scottish Medicines Consortium (SMC) has approved palbociclib (Ibrance)1 for use by NHS Scotland, Angela Harris...

Responding to new ONS figures showing that one year survival rates for breast cancer in England have reached 96.7%, Dr Emma Pennery, Clinical Director at...

Responding to findings from Imperial College London exploring the link between excess weight, diabetes and breast cancer, Carolyn Rogers, Senior Clinical...

Responding to the decision from NICE that palbociclib (Ibrance) and ribociclib (Kisqali)* have been approved for use on the NHS in England, Samia al...

Responding to Louise Wilson (played by Pooky Quesnel) in The A Word being diagnosed with breast cancer, Samia al Qadhi, Chief Executive of Breast Cancer...

Thursday 9 November 2017: Responding to the announcement that NHS England and Roche have reached a commercial agreement in principle on the use of...